Capital Preferences in U.S. Biopharma Investments (2005–2014): R&D Stage Dominates Funding Flows
This report is authorized by Yuanxu Capital for republication by VCBeat. Authored byYuanxu InvestmentPartner Zhang Xing (WeChat ID: AlwaysForTruth),Yuanxu InvestmentDedicated to assisting Chinese investment institutions and industrial capital in strategically positioning themselves within the U.S. biomedicine and healthcare industry.
Investment in the U.S. biopharmaceutical industry is generally evaluated from two dimensions: (1) the stage of technological development of the project’s product, and (2) the application area of the project’s product technology (typically categorized by disease). In this article, I will review and analyze the first aspect, namely, investment trends in U.S. biopharmaceutical projects at different development stages.
In this article, projects are categorized into two major groups based on their development stage: the R&D stage (products not yet approved by the FDA) and the market stage (products already approved by the FDA but with annual sales below $1 billion).
U.S. biopharmaceutical companies have four primary sources of financing: venture capital, initial public offerings (IPOs), follow-on public offerings, and mergers and acquisitions (M&A). Notably, the U.S. secondary market exhibits a high level of acceptance for biotechnology and drug development projects, allowing numerous companies still in the R&D stage to go public and continue raising capital in the secondary market.
Overall Investment Trends, 2005–2014
Over the past decade, a total of $92.3 billion in investment (excluding mergers and acquisitions) flowed into U.S. biopharmaceutical projects, with the majority of capital favoring projects still in the R&D stage. Most investments entered these projects through venture capital and secondary stock offerings (Figure 4.1), primarily reflecting two strategies employed by U.S. investors: entering early-stage projects as soon as possible to maximize returns, and waiting for FDA approval before investing in late-stage projects. In sharp contrast, marketed-stage projects dominated the M&A landscape, attracting approximately two-thirds of such investment. Furthermore, R&D-stage projects generated $35.9 billion in revenue through technology licensing, nearly equivalent to the $37.1 billion raised via venture capital.
Venture Capital
Between 2005 and 2014, the majority of venture capital was invested in the research and development (R&D) of new drugs, while R&D for existing drugs (e.g., novel drug delivery systems) consistently attracted only a small fraction of venture capital (Figure 4.2). Venture capital investment peaked in 2007 at $4.98 billion. However, venture capital specifically directed toward new drug R&D reached its peak in 2014 at $4 billion. In recent years, venture capital has become increasingly concentrated at two ends of the spectrum, with investments primarily allocated to the preclinical and Phase II clinical trial stages, dropping sharply after Phase II (Figure 4.3). This trend is mainly driven by the fact that many biopharmaceutical companies pursue initial public offerings (IPOs) shortly after successfully completing Phase II clinical trials.
Taking Series A financing as an example, preclinical companies accounted for 56%, and companies in Phase I clinical trials accounted for 18%. Between 2005 and 2014, total Series A financing amounted to $10.9 billion, representing 28% of the total venture capital investment. From 2011 to 2014, the annual total for Series A financing remained around $900 million.
IPO
During the 2008 financial crisis, biopharmaceutical IPOs suffered a devastating blow. They gradually recovered thereafter, began to rise strongly in 2013, and reached a historical peak in 2014 (Figure 4.4). In 2012, the United States passed the JOBS Act (Jumpstart Our Business Startups), which significantly lowered the threshold for IPOs and boosted secondary market confidence in companies at the R&D stage. Between 2008 and 2011, no U.S. company still in Phase I clinical trials or earlier stages went public; however, from 2012 to 2014, 22 companies in Phase I clinical trials or earlier stages completed their IPOs. The average fundraising amount for R&D-stage companies that went public between 2005 and 2007 was $50 million, with a total of $2.1 billion raised; between 2012 and 2014, the average fundraising amount for IPO companies was $72 million, with a total of $7 billion raised.
Additional Share Issuance
Following a company’s initial public offering (IPO), significant R&D milestones—such as clinical trial results—will have an immediate and direct impact on its stock price. If clinical trial outcomes are favorable, the company can raise capital for subsequent product development and commercialization through follow-on equity offerings (Figure 4.5). More than half of the funds raised via such secondary offerings have gone to companies with products in Phase III clinical trials, many of which have secured substantially more capital through these offerings than they did during their IPOs. In recent years, it has become increasingly common for companies to raise over $10 million in a single follow-on offering. Notably, projects at the market stage account for one-quarter of the total number of projects but attract one-third of the total capital raised.
M&A
Between 2005 and 2014, the total value of global biopharmaceutical mergers and acquisitions reached $208 billion (excluding contingent value rights) (Figure 4.6). Of this amount, $76 billion (37%) was attributed to projects in the R&D stage, while $131 billion (63%) involved products already on the market. For R&D-stage projects, 2011 marked the peak, driven by the $11 billion acquisition of Pharmasset (which was then in Phase II clinical trials). Excluding 2011, the highest value was recorded in 2014 at $9.6 billion, primarily due to the acquisition of multiple Phase III clinical projects.
Products in Development
According to statistics, companies in the R&D and commercialization stages currently have a total of approximately 3,415 drugs under development, accounting for about 69% of the global biopharmaceutical industry’s pipeline. Among these 3,415 investigational drugs, Phase I, Phase II, and Phase III clinical trials account for 29% (1,004 drugs), 55% (1,877 drugs), and 16% (534 drugs), respectively. The distribution of drug types spans several major therapeutic areas of high interest (Figure 4.7).
Of the 3,415 drugs under development, approximately 43% involve collaborative R&D efforts with other companies in the industry. Notably, late-stage projects exhibit a higher rate of collaboration than early-stage ones. For instance, only 36% of drugs in Phase I clinical trials involve inter-company collaborations, whereas 51% of those in Phase III clinical trials do.
Summary
Biopharmaceutical investments are concentrated in two stages: pre-IPO venture capital and post-IPO follow-on equity offerings;
Venture capital is concentrated in new drug development, particularly in the preclinical (drug discovery) and Phase II clinical trial stages.
Biopharmaceutical companies often go public before obtaining FDA approval, most commonly at the conclusion of Phase II clinical trials, and raise capital through secondary offerings to fund subsequent product development, regulatory approvals, and other activities.
The drug pipeline is primarily composed of Phase II clinical candidates, with a focus on oncology and immunology.
The M&A targets are primarily companies with FDA-approved products.